Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 19 of 28.
Apr 2014
15 Apr · Updates
Company through its Swiss subsidiary has received USD 5 million as milestone payment from Sanofi on a collaboration of its VLA2 (alpha2-beta1) integrin monoclonal antibody. GBR 500 is a first-in-class therapeutic monoclonal antibody for chronic autoimmune disorders. Glenmark has received from Sanofi already USD 50 Mn as an upfront payment in FY2011-12. Hence, the total amount received by Glenmark from Sanofi for its first in class VLA-2 monoclonal antibody is USD 55 million.
Mar 2014
25 Mar · Updates
Company through its Swiss Subsidiary has received USD 4 million as research fee payment from Forest Laboratories Inc. on a collaboration for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain. Under the terms of the agreement signed in FY 2012-13, Forest made USD 6 million upfront payment and also provided an additional USD 3 million to support the next phase of work. In September 2013, Glenmark received an additional amount of USD 2 million as research fee payment from Forest Laboratories Inc. Hence, the total amount received by Glenmark from Forest Laboratories Inc towards its novel mPEGS-1 inhibitors program is USD 15 million.
Feb 2014
Jan 2014
24 Jan · Business
Board of Directors of the Company, at its Meeting held on January 24, 2014 allotted 57,600 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.24 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2013 as follows: Net Sales of Rs. 160122.3 lacs for the quarter ending on 31-DEC-2013 . Net Profit / (Loss) of Rs. 21623.6 lacs for the quarter ending on 31-DEC-2013.24 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2013 as follows: Net Sales of Rs. 53031.8 lacs for the quarter ending on 31-DEC-2013 against Rs. 58302.6 lacs and Rs. 53489.1 lacs for the quarters ending on 30-SEP-2013 and 31-DEC-2012 respectively. Net Profit / (Loss) of Rs. 5840.9 lacs for the quarter ending on 31-DEC-2013 against Rs. 10594.8 lacs and Rs. 10903.6 lacs for the quarters ending on 30-SEP-2013 and 31-DEC-2012 respectively.14 Jan · Board meeting
To consider and approve the Company's Un-audited Financial Statements for the Third Quarter ended December 31, 2013.
Dec 2013
Nov 2013
28 Nov · Disclosure
Operations Committee of the Board of Directors of the Company at its meeting held on November 27, 2013 allotted 1,09,400 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
Oct 2013
31 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2013 as follows: Net Sales of Rs. 146300.6 lacs for the quarter ending on 30-SEP-2013 . Net Profit / (Loss) of Rs. 15429.7 lacs for the quarter ending on 30-SEP-2013.31 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2013 as follows: Net Sales of Rs. 58302.6 lacs for the quarter ending on 30-SEP-2013 against Rs. 50797.8 lacs and Rs. 52598.1 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively. Net Profit / (Loss) of Rs. 10594.8 lacs for the quarter ending on 30-SEP-2013 against Rs. 11779.9 lacs and Rs. 13732.7 lacs for the quarters ending on 30-JUN-2013 and 30-SEP-2012 respectively.21 Oct · Board meeting
To consider and approve the Company's un-audited Financial Statements for the Second Quarter/Half year ended September 30, 2013.
Sep 2013
25 Sep · Disclosure
Operations Committee of the Board of Directors of the Company, at its Meeting held on September 24, 2013 allotted 4,600 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
Aug 2013
19 Aug · Disclosure
Operations Committee of the Board of Directors of the Company, at its Meeting held on August 17, 2013 allotted 61,300 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.2 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2013
19 Jul · Board meeting
To consider and approve the Company's Un-audited Financial Statements for the First Quarter ended 30th June, 2013.18 Jul · Disclosure
Operations Committee of the Board of Directors of the Company, at its Meeting held on July 18, 2013 allotted 21,800 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.5 Jul · Meeting
Register of Members and the Share Transfer Books of the Company will remain closed from July 22, 2013 to August 02, 2013 (both days inclusive) for the purpose of the Annual Closure for the Annual General Meeting scheduled to be held on August 02, 2013 and also for determining the names of the shareholders to whom the dividend which if declared at the Annual General Meeting is payable.
Jun 2013
17 Jun · Business
Operations Committee of the Board of Directors of the Company, at its Meeting held on June 17, 2013 allotted 11,800 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.